Home›Stocks›BBIO

BBIO — structural market context

BridgeBio Pharma, Inc.

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Oct 14. Each line shows the earlier value, the later value and their dates.

Price

Close $64.94 (Oct 14) vs $63.30 (Oct 13): +2.59%.

Volume

0.88× its 20-session average (3.1M) on Oct 14.

Includes pre- and post-market trading.

Short interest

Short interest 19.7M shares (settlement Sep 30) vs 21.5M (Sep 15).

No new publication in this window. Latest: settlement Sep 30, published Oct 10.

Fails-to-deliver

Latest file (settlements Sep 1–Sep 14, published Sep 30): 6 days with fails, largest 50K shares on Sep 14.

Previous file (settlements Aug 17–Aug 31, published Sep 16): 2 days with fails, largest 57 shares on Aug 25.

No new publication in this window.

Analyst rating actions

None recorded in this window.

Insider filings (Form 4)

None recorded in this window.

BBIO short interest & days to cover

SHARES SHORT
19.7M
% OF FLOAT
—
DAYS TO COVER
5.8
CHANGE VS PRIOR
-8.7%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-09-30 (17d ago)

BBIO fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-09-18 · 29d5K$67.31
2026-09-14 · 33d50K$72.44
2026-09-11 · 36d105$72.5

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

BBIO insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 0 purchases · 9 sales

InsiderTypeSharesValueFiled
Kumar Neil · director, officer: Chief Executive OfficerSell (S)1K$89K2026-09-21
Kumar Neil · director, officer: Chief Executive OfficerSell (S)9K$602K2026-09-21
Kumar Neil · director, officer: Chief Executive OfficerSell (S)1K$100K2026-08-20
Kumar Neil · director, officer: Chief Executive OfficerSell (S)8K$679K2026-08-20
Kumar Neil · director, officer: Chief Executive OfficerSell (S)2K$152K2026-08-20

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

BBIO analyst ratings

FirmActionRatingPublished
UBSprice_target—2026-10-15
Barclaysprice_target—2026-10-07
William BlairholdOutperform2026-10-06
H.C. WainwrightholdBuy2026-10-06
JefferiesholdBuy2026-10-05

Rating actions as published by the firms, from public feeds. They are not graded here.

Frequently asked questions

Are insiders buying BBIO?
In the last 12 months of SEC Form 4 filings, BBIO recorded 0 insider purchases and 9 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.
What do analysts say about BBIO?
The most recent action: UBS price_target on 2026-10-15. Rating actions are shown as published by the firms; they are not graded here.
Is this page telling me to buy or sell BBIO?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

More tickers starting with B

BABA · Alibaba Group Holding LimitedBE · Bloom Energy CorporationBTI · British American Tobacco p.l.cBBNX · Beta Bionics, Inc. Common StocBCDA · BioCardia, Inc.BELFB · Bel Fuse Inc.All B →

This is the teaser.

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.